OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.

Registration to our newsletter is FREE, Join today by entering your email below!

Tag Archives: cxm

Can Cardium Therapeutics (AMEX: CXM) Capitalize on FDA Approval and Commercialization Deal During First Quarter 2012?

Posted on January 9, 2012 by Editor

Shareholders of Cardium Therapeutics (AMEX: CXM) have endured a lot over the years, waiting patiently for the day when the biotechnology company would gain FDA approval for a product and begin generating meaningful revenue. In October 2011 CXM received that … Continue reading →

Posted in AMEX, Articles, Penny Stocks | Tagged , , , , , , , , | Leave a comment

Cardium Therapeutics (AMEX: CXM) Receives FDA Clearance to Market and Sell Excellagen, Technology Platform Could Birth New Product Lines

Posted on October 12, 2011 by Editor

Cardium Therapeutics (AMEX: CXM) has been battling for nearly two years to receive 510(k) clearance from the FDA to market and sell their Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other … Continue reading →

Posted in AMEX, Articles, Penny Stocks | Tagged , , , , , , , , , , | Leave a comment

Healthcare Stocks Posting Largest Percentage Gains: PARD, BLTI, CO, CXM, BASI

Posted on December 16, 2010 by OTC Equity

Healthcare stocks managed to close out Thursday up 0.53% as a sector with several companies posting double-digit percentage gains for the day. Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) put together the biggest jump as shares climbed 28.21% to close at 0.50. … Continue reading →

Posted in AMEX, NASDAQ, News | Tagged , , , , , , , , , , , , , | Leave a comment

Cardium Therapeutics, Inc. Remains in Limbo as FDA Approval for Excellagen Remains Questionable

Posted on November 5, 2010 by Editor

It has been nearly a year since Cardium Therapeutics, Inc. (AMEX: CXM) submitted their FDA 501(k) application for approval to market and sell their wound care management topical gel product Excellagen and investors are getting antsy as the delay continues … Continue reading →

Posted in AMEX, Articles | Tagged , , , , , , , , , , | Leave a comment